B. Riley reduced PDS Biotechnology’s price target to $3 from $5 but maintains a Buy rating, citing undervaluation and strategic advantages. The firm highlights enrollment size, efficacy endpoint durations, and an enriched p16+ve population as factors not yet reflected in the stock price.

Source: TheFly

For more information on PDS Biotechnology, visit TipRanks for insider trading stocks and important disclosures.

Disclaimer & Disclosure: Contact the editor to report any issues.

Read more at Yahoo Finance: PDS Biotechnology price target lowered to $3 from $5 at B. Riley